Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review ; volume:12 ; number:11 ; day:25 ; month:9 ; year:2022 ; pages:2489-2497 ; date:11.2022
Dermatology and therapy ; 12, Heft 11 (25.9.2022), 2489-2497, 11.2022
- Urheber
-
Najmi, Maleka
Tran, Tiffaney
Witt, Russell G.
Nelson, Kelly C.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-022-00810-1
- URN
-
urn:nbn:de:101:1-2023010621095833207747
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Najmi, Maleka
- Tran, Tiffaney
- Witt, Russell G.
- Nelson, Kelly C.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Dysbiosis of skin microbiome and gut microbiome in melanoma progression
Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors
Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
Predicting response to immunotherapy in metastatic melanoma by a personalized mathematical model
Immunotherapy of malignant melanoma
Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
METASTATIC MALIGNANT MELANOMA OF SKIN
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Dysbiosis of skin microbiome and gut microbiome in melanoma progression